In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apeiron Biologics AG

www.apeiron-biologics.com

Latest From Apeiron Biologics AG

BIO-Europe Spring 2019: Apeiron CEO On Pipeline Progress And Partnering

Peter Llewellyn-Davies, CEO and chief financial officer of Apeiron Biologics, talks to Lucie Ellis, executive editor of In Vivo, on the sidelines of the recent BIO-Europe Spring conference about the company’s pipeline and partnering strategy.

Companies ImmunoOncology

Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership

Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.

Deals Intellectual Property

Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program

Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.

Deals Research & Development

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Liposomes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Apeiron Biologics GMBH
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Austria
  • Parent & Subsidiaries
  • Apeiron Biologics AG
  • Senior Management
  • Peter Llewellyn-Davies, Pres. & CEO & CFO
    Anderson Gaweco, MD, PhD, CMO & CSO
  • Contact Info
  • Apeiron Biologics AG
    Phone: (43) 865 65 77
    Campus-Vienna-Biocenter 5
    Vienna, A-1030
    Austria
Advertisement
Advertisement
UsernamePublicRestriction

Register